Aminopyrimidinones as interleukin receptor-associated kinase inhibitors

摘要

This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

主权项

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof; wherein; X is —N═; Y is —NR2—, wherein R2 and R3 together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclic ring selected from  optionally substituted with 1 to 3 substituents independently selected from methyl, ethyl, propyl, hydroxy, halogen, methoxy, and ethoxy; R1 is selected from the group consisting of: C1-6 alkyl, C3-6 cycloalkyl, aryl, and heterocyclyl; and R6 is selected from the group consisting of: C1-6 alkyl, C3-6 cycloalkyl, aryl, and heterocyclyl; wherein each of the C1-6 alkyl, C3-6 cycloalkyl, aryl and heterocyclyl of R1 and R6 are optionally substituted with 1-3 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, oxo, and halogen.